Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Crispr, Vertex announce FDA RMAT designation granted to CTX001 » 09:37
05/11/20
05/11
09:37
05/11/20
09:37
CRSP

Crispr Therapeutics

$53.84 /

+0.39 (+0.73%)

, VRTX

Vertex

$271.34 /

+1.4 (+0.52%)

CRISPR Therapeutics…

CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals Incorporated (VRTX) announced that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to CTX001, an investigational, autologous, gene-edited hematopoietic stem cell therapy, for the treatment of severe sickle cell disease and transfusion-dependent beta thalassemia. Established under the 21st Century Cures Act, RMAT designation is a dedicated program designed to expedite the drug development and review processes for promising pipeline products, including genetic therapies. A regenerative medicine therapy is eligible for RMAT designation if it is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or therapy has the potential to address unmet medical needs for such disease or condition. Similar to Breakthrough Therapy designation, RMAT designation provides the benefits of intensive FDA guidance on efficient drug development, including the ability for early interactions with FDA to discuss surrogate or intermediate endpoints, potential ways to support accelerated approval and satisfy post-approval requirements, potential priority review of the biologics license application and other opportunities to expedite development and review. In addition to RMAT designation, CTX001 has received Orphan Drug Designation from the U.S. FDA for TDT and from the European Commission for TDT and SCD. CTX001 also has Fast Track Designation from the U.S. FDA for both TDT and SCD.

ShowHide Related Items >><<
CRSP Crispr Therapeutics
$53.84 /

+0.39 (+0.73%)

04/29/20 Raymond James
Crispr progress not enough to change bearish view, says Raymond James
04/28/20 Piper Sandler
Piper backs Overweight on Crispr after Q1 results
04/27/20 Piper Sandler
Piper backs Overweight on Vertex after new Affinia partnership
04/01/20 Piper Sandler
Crispr Therapeutics study halts not unexpected, says Piper Sandler
VRTX Vertex
$271.34 /

+1.4 (+0.52%)

04/30/20 SVB Leerink
Vertex price target raised to $263 from $224 at SVB Leerink
04/30/20 H.C. Wainwright
Vertex price target raised to $295 from $270 at H.C. Wainwright
04/28/20
RBC Capital downgraded Vertex to Sector Perform on valuation
04/28/20 RBC Capital
Vertex downgraded to Sector Perform from Outperform at RBC Capital
Conference/Events
Crispr Therapeutics participates in a conference call hosted by SunTrust » 08:55
05/06/20
05/06
08:55
05/06/20
08:55
CRSP

Crispr Therapeutics

$52.02 /

+2.09 (+4.19%)

SunTrust Biotech Analyst…

SunTrust Biotech Analyst holds a conference call with CEO Kulkami and CFO Tomsicek. on May 6 at 10 am.

ShowHide Related Items >><<
CRSP Crispr Therapeutics
$52.02 /

+2.09 (+4.19%)

04/29/20 Raymond James
Crispr progress not enough to change bearish view, says Raymond James
04/28/20 Piper Sandler
Piper backs Overweight on Crispr after Q1 results
04/27/20 Piper Sandler
Piper backs Overweight on Vertex after new Affinia partnership
04/01/20 Piper Sandler
Crispr Therapeutics study halts not unexpected, says Piper Sandler
Conference/Events
Crispr Therapeutics participates in a conference call hosted by SunTrust » 07:24
05/05/20
05/05
07:24
05/05/20
07:24
CRSP

Crispr Therapeutics

$49.93 /

+1.44 (+2.97%)

SunTrust Biotech Analyst…

SunTrust Biotech Analyst holds a conference call with CEO Kulkami and CFO Tomsicek. on May 6 at 10 am.

ShowHide Related Items >><<
CRSP Crispr Therapeutics
$49.93 /

+1.44 (+2.97%)

04/29/20 Raymond James
Crispr progress not enough to change bearish view, says Raymond James
04/28/20 Piper Sandler
Piper backs Overweight on Crispr after Q1 results
04/27/20 Piper Sandler
Piper backs Overweight on Vertex after new Affinia partnership
04/01/20 Piper Sandler
Crispr Therapeutics study halts not unexpected, says Piper Sandler
Hot Stocks
Vertex has temporarily paused or delayed enrollment in certain studies » 16:11
04/29/20
04/29
16:11
04/29/20
16:11
VRTX

Vertex

$252.06 /

-5.04 (-1.96%)

, CRSP

Crispr Therapeutics

$52.06 /

-0.42 (-0.80%)

Vertex (VRTX) continues…

Vertex (VRTX) continues to progress its expanding pipeline of programs in the clinic, which span various diseases, modalities and stages of development. To ensure patient safety and reduce the burden on the healthcare system at a time of critical need, Vertex has temporarily paused or delayed enrollment in certain studies. Vertex has temporarily paused screening and enrollment in the Phase 2 study of VX-814; however, the study remains active and Vertex continues to initiate new clinical trial sites to enable future patient enrollment. Vertex and its partner CRISPR Therapeutics (CRSP) remain on track to provide additional data from the two ongoing Phase 1/2 studies of the investigational CRISPR/Cas9 gene-editing therapy CTX001 in patients with transfusion-dependent beta thalassemia and in patients with severe sickle cell disease in 2020. New data expected in 2020 include initial data from additional patients dosed in each of the Phase 1/2 studies and longer duration follow-up data for the first patients dosed in each study. Screening, enrollment and mobilization in these studies is ongoing; however, no additional patients are scheduled to initiate conditioning or dosing at this time.

ShowHide Related Items >><<
VRTX Vertex
$252.06 /

-5.04 (-1.96%)

04/28/20
RBC Capital downgraded Vertex to Sector Perform on valuation
04/28/20 RBC Capital
Vertex downgraded to Sector Perform from Outperform at RBC Capital
04/27/20 Piper Sandler
Piper backs Overweight on Vertex after new Affinia partnership
03/27/20 Piper Sandler
Vertex's 2020 business outlook not impacted by COVID-19, says Piper Sandler
CRSP Crispr Therapeutics
$52.06 /

-0.42 (-0.80%)

04/29/20 Raymond James
Crispr progress not enough to change bearish view, says Raymond James
04/28/20 Piper Sandler
Piper backs Overweight on Crispr after Q1 results
04/01/20 Piper Sandler
Crispr Therapeutics study halts not unexpected, says Piper Sandler
Recommendations
Crispr progress not enough to change bearish view, says Raymond James » 10:36
04/29/20
04/29
10:36
04/29/20
10:36
CRSP

Crispr Therapeutics

$51.25 /

-1.23 (-2.34%)

Raymond James analyst…

Raymond James analyst Steven Seedhouse maintains an Underperform rating on Crispr Therapeutics following the company's Q1 results. The analyst says that while the company has made a lot of clinical progress, here's not enough data to change his bearish view.

ShowHide Related Items >><<
CRSP Crispr Therapeutics
$51.25 /

-1.23 (-2.34%)

04/28/20 Piper Sandler
Piper backs Overweight on Crispr after Q1 results
04/27/20 Piper Sandler
Piper backs Overweight on Vertex after new Affinia partnership
04/01/20 Piper Sandler
Crispr Therapeutics study halts not unexpected, says Piper Sandler
03/04/20 Stifel
Crispr Therapeutics initiated with a Hold at Stifel
Recommendations
Piper backs Overweight on Crispr after Q1 results » 18:53
04/28/20
04/28
18:53
04/28/20
18:53
CRSP

Crispr Therapeutics

$52.48 /

-2.47 (-4.49%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $104 price target on Crispr Therapeutics after the company reported Q1 results. Tenthoff noted that despite closing intermission, Crispr plans to present new patient data and longer duration data form the first beta-thal and SCD patients in 2020. The analyst added that risks to his rating include that the CRISPR/CAS9 technology is unproven and may fail.

ShowHide Related Items >><<
CRSP Crispr Therapeutics
$52.48 /

-2.47 (-4.49%)

04/27/20 Piper Sandler
Piper backs Overweight on Vertex after new Affinia partnership
04/01/20 Piper Sandler
Crispr Therapeutics study halts not unexpected, says Piper Sandler
03/04/20 Stifel
Crispr Therapeutics initiated with a Hold at Stifel
02/13/20 Piper Sandler
Crispr Therapeutics ended year with $943M in cash, says Piper Sandler
Earnings
CRISPR Therapeutics reports Q1 EPS ($1.15), consensus ($1.05) » 16:46
04/28/20
04/28
16:46
04/28/20
16:46
CRSP

Crispr Therapeutics

$52.48 /

-2.47 (-4.49%)

Reports Q1 collaboration…

Reports Q1 collaboration revenue $157,000. "We made substantial progress in the last quarter despite the challenges posed by COVID-19. We are now progressing five cell therapy clinical trials in parallel targeting hemoglobinopathies and various cancers," said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics. "Our CTX001 and CTX110 programs continue to enroll patients, and we expect to report data for these programs this year. We are pleased to have begun treating patients in our CTX120 trial for the treatment of relapsed or refractory multiple myeloma and we expect to begin treating patients in our CTX130 trial in renal cell carcinoma and T-cell and B-cell hematologic malignancies in the second half of this year. Despite these unprecedented times, we continue to execute on our programs and we remain focused on our commitment to patients and their families."

ShowHide Related Items >><<
CRSP Crispr Therapeutics
$52.48 /

-2.47 (-4.49%)

04/27/20 Piper Sandler
Piper backs Overweight on Vertex after new Affinia partnership
04/01/20 Piper Sandler
Crispr Therapeutics study halts not unexpected, says Piper Sandler
03/04/20 Stifel
Crispr Therapeutics initiated with a Hold at Stifel
02/13/20 Piper Sandler
Crispr Therapeutics ended year with $943M in cash, says Piper Sandler
Recommendations
Piper backs Overweight on Vertex after new Affinia partnership » 12:06
04/27/20
04/27
12:06
04/27/20
12:06
VRTX

Vertex

$271.94 /

+2.09 (+0.77%)

, CRSP

Crispr Therapeutics

$55.72 /

+1.66 (+3.07%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $300 price target on Vertex Pharmaceuticals (VRTX) after it entered into a partnership with Affinia Therapeutics to use its adeno-associated virus platform to develop gene editing medicines with partner CRISPR Therapeutics (CRSP) in duchenne muscular dystrophy, myotonic dystrophy type 1, and cystic fibrosis. Tenthoff, who noted that Vertex will report earnings this week, said that the partnership will "bolster" Vertex's DMD efforts. The analyst also noted that Vertex previously guided that the COVID-19 pandemic has not interrupted commercial supply of Trikafta or its other CF therapies.

ShowHide Related Items >><<
VRTX Vertex
$271.94 /

+2.09 (+0.77%)

03/27/20 Piper Sandler
Vertex's 2020 business outlook not impacted by COVID-19, says Piper Sandler
03/18/20 Citi
Vertex's lower COVID exposure makes shares 'compelling,' says Citi
03/13/20 Jefferies
Large-cap biotech remains good 'defensive zone' for 2020, says Jefferies
03/12/20 Wolfe Research
Vertex initiated with an Outperform at Wolfe Research
CRSP Crispr Therapeutics
$55.72 /

+1.66 (+3.07%)

04/01/20 Piper Sandler
Crispr Therapeutics study halts not unexpected, says Piper Sandler
03/04/20 Stifel
Crispr Therapeutics initiated with a Hold at Stifel
02/13/20 Piper Sandler
Crispr Therapeutics ended year with $943M in cash, says Piper Sandler
02/03/20 Evercore ISI
Evercore ISI downgrades Crispr Therapeutics, questions relative valuation
Over a month ago
Conference/Events
Wells Fargo to hold a virtual conference » 08:13
04/07/20
04/07
08:13
04/07/20
08:13
ADAP

Adaptimmune

$3.01 /

+0.38 (+14.45%)

, AFMD

Affimed N.V.

$1.83 /

+0.23 (+14.38%)

, AKCA

Akcea Therapeutics

$15.74 /

+1.19 (+8.18%)

, AGTC

Applied Genetic

$3.38 /

+0.4 (+13.42%)

, ARNA

Arena Pharmaceuticals

$47.33 /

+2.24 (+4.97%)

, AUTL

Autolus Therapeutics

$6.35 /

+1 (+18.69%)

, AVRO

Avrobio

$14.99 /

+1.62 (+12.12%)

, BLUE

Bluebird Bio

$43.52 /

+1.64 (+3.92%)

, CYAD

Celyad

$7.92 /

+0.92 (+13.14%)

, CRSP

Crispr Therapeutics

$42.26 /

+2.81 (+7.12%)

, GRTS

Gritstone Oncology

$6.62 /

+0.36 (+5.75%)

, IMV

IMV Inc.

$1.69 /

+0.03 (+1.81%)

, INFI

Infinity Pharmaceuticals

$0.89 /

+0.0875 (+10.94%)

, JNCE

Jounce Therapeutics

$4.96 /

+0.68 (+15.89%)

, MEIP

MEI Pharma

$1.55 /

+0.07 (+4.73%)

, MNTA

Momenta

$27.93 /

+3.93 (+16.38%)

, MYOK

MyoKardia

$47.96 /

+1.52 (+3.27%)

, QURE

uniQure

$47.77 /

+2.39 (+5.27%)

, VYGR

Voyager Therapeutics

$8.92 /

+0.79 (+9.72%)

2020 Wells Fargo Biotech…

2020 Wells Fargo Biotech Virtual Corporate Access Day will be held on April 7. Webcast Link

ShowHide Related Items >><<
ADAP Adaptimmune
$3.01 /

+0.38 (+14.45%)

10/23/19
Adaptimmune management to meet with SunTrust
08/02/19
Fly Intel: Top five analyst downgrades
08/02/19 Guggenheim
Adaptimmune downgraded to Neutral on low near-term visibility at Guggenheim
08/01/19 Guggenheim
Adaptimmune downgraded to Neutral from Buy at Guggenheim
AFMD Affimed N.V.
$1.83 /

+0.23 (+14.38%)

AKCA Akcea Therapeutics
$15.74 /

+1.19 (+8.18%)

01/22/20 Stifel
Akcea LICA data look 'solid,' as expected, says Stifel
10/08/19 BMO Capital
Akcea Therapeutics price target lowered to $39 from $43 at BMO Capital
10/07/19 Stifel
Pfizer deal a 'solid, unexpected' win for Akcea Therapeutics, says Stifel
10/07/19
Akcea Therapeutics upgraded to Outperform on Pfizer partnership at Wells Fargo
AGTC Applied Genetic
$3.38 /

+0.4 (+13.42%)

02/12/20 Roth Capital
Applied Genetic in position to execute after cash raise, says Roth Capital
01/28/20
Fly Intel: Top five analyst initiations
01/27/20 Roth Capital
Applied Genetic initiated with a Buy at Roth Capital
01/09/20 BMO Capital
Applied Genetic price target raised to $16 from $9 at BMO Capital
ARNA Arena Pharmaceuticals
$47.33 /

+2.24 (+4.97%)

03/31/20 Guggenheim
Guggenheim starts Arena at Buy on 'pipeline-in-a-product' etrasimod
03/31/20 Guggenheim
Arena Pharmaceuticals initiated with a Buy at Guggenheim
03/26/20 BofA
Arena Pharmaceuticals upgraded to Buy on recent selloff at BofA
03/26/20 BofA
Arena Pharmaceuticals upgraded to Buy from Neutral at BofA
AUTL Autolus Therapeutics
$6.35 /

+1 (+18.69%)

02/18/20 H.C. Wainwright
Now the time to get long Autolus Therapeutics, says H.C. Wainwright
09/23/19 Needham
Autolus Therapeutics initiated with a Buy at Needham
09/23/19 Needham
Autolus Therapeutics initiated with a Buy at Needham
09/12/19 H.C. Wainwright
Autolus' Woodford overhang in the rearview, says H.C. Wainwright
AVRO Avrobio
$14.99 /

+1.62 (+12.12%)

03/31/20 H.C. Wainwright
Avrobio downgraded to Neutral from Buy at H.C. Wainwright
03/17/20 Janney Montgomery Scott
Avrobio weakness a buying opportunity, says Janney Montgomery Scott
02/19/20 Nomura Instinet
Avrobio price target raised to $50 from $35 at Nomura Instinet
02/11/20 Mizuho
Avrobio price target raised to $35 from $28 at Mizuho
BLUE Bluebird Bio
$43.52 /

+1.64 (+3.92%)

03/27/20 BMO Capital
Bluebird Bio price target lowered to $107 from $132 at BMO Capital
03/26/20
Bluebird Bio upgraded to Buy from Hold at Stifel
03/26/20 Stifel
Bluebird Bio upgraded to Buy from Hold at Stifel
03/26/20 Piper Sandler
Bluebird Bio price target lowered to $75 from $85 at Piper Sandler
CYAD Celyad
$7.92 /

+0.92 (+13.14%)

03/26/20 Wells Fargo
Celyad price target lowered to $20 from $44 at Wells Fargo
03/25/20 H.C. Wainwright
Celyad price target lowered to $37 from $43 at H.C. Wainwright
07/05/19 H.C. Wainwright
Celyad target lowered to $48 on new launch timeline at H.C. Wainwright
07/05/19 Piper Sandler
Celyad price target lowered to $25 from $41 at Piper Jaffray
CRSP Crispr Therapeutics
$42.26 /

+2.81 (+7.12%)

04/01/20 Piper Sandler
Crispr Therapeutics study halts not unexpected, says Piper Sandler
03/04/20 Stifel
Crispr Therapeutics initiated with a Hold at Stifel
02/13/20 Piper Sandler
Crispr Therapeutics ended year with $943M in cash, says Piper Sandler
02/03/20 Evercore ISI
Evercore ISI downgrades Crispr Therapeutics, questions relative valuation
GRTS Gritstone Oncology
$6.62 /

+0.36 (+5.75%)

07/26/19
Fly Intel: Top five analyst initiations
07/25/19 Baird
Gritstone Oncology initiated with an Outperform at Baird
IMV IMV Inc.
$1.69 /

+0.03 (+1.81%)

04/01/20 B. Riley FBR
IMV Inc. downgraded to Neutral from Buy at B. Riley FBR
03/18/20 Raymond James
IMV Inc. downgraded to Market Perform from Outperform at Raymond James
02/28/20 B. Riley FBR
IMV Inc. selloff this weekend is overdone, says B. Riley FBR
02/25/20 H.C. Wainwright
IMV's DeCidE1 results 'quite encouraging,' says H.C. Wainwright
INFI Infinity Pharmaceuticals
$0.89 /

+0.0875 (+10.94%)

11/18/19 B. Riley FBR
Infinity Pharmaceuticals resumed with a Buy at B. Riley FBR
06/27/19
Fly Intel: Top five analyst initiations
06/27/19
Oppenheimer bullish on Infinity Pharmaceuticals, initiates with an Outperform
06/26/19 Oppenheimer
Infinity Pharmaceuticals initiated with an Outperform at Oppenheimer
JNCE Jounce Therapeutics
$4.96 /

+0.68 (+15.89%)

03/25/20 Raymond James
Jounce upgraded to Strong Buy ahead of cancer data at Raymond James
03/25/20 Raymond James
Jounce Therapeutics upgraded to Strong Buy from Outperform at Raymond James
MEIP MEI Pharma
$1.55 /

+0.07 (+4.73%)

MNTA Momenta
$27.93 /

+3.93 (+16.38%)

04/02/20 H.C. Wainwright
Momenta's Vivacity-MG still on track despite COVID-19, says H.C. Wainwright
04/02/20 Piper Sandler
Piper Sandler says enrollment delays already priced into Momenta shares
03/12/20
Fly Intel: Top five analyst initiations
03/12/20 Goldman Sachs
Momenta initiated with a Neutral at Goldman Sachs
MYOK MyoKardia
$47.96 /

+1.52 (+3.27%)

03/31/20 Cantor Fitzgerald
MyoKardia's MAVERICK data keeps Cantor Fitzgerald 'positive'
02/11/20 Credit Suisse
MyoKardia price target raised to $82 from $77 at Credit Suisse
02/07/20 JPMorgan
MyoKardia shares can reach $100-$115 on positive data, says JPMorgan
01/27/20 Guggenheim
Guggenheim has high conviction in MyoKardia trial after cardiologist survey
QURE uniQure
$47.77 /

+2.39 (+5.27%)

03/26/20 Piper Sandler
uniQure trial delay 'comes as no surprise,' says Piper Sandler
01/23/20 Cantor Fitzgerald
Cantor sees further upside in uniQure, calls 'highly attractive' buyout candiate
12/10/19 Mizuho
uniQure price target raised to $90 from $67 at Mizuho
12/09/19 Piper Sandler
Piper says uniQure solidified 'front runner' position in Hemophilia B at ASH
VYGR Voyager Therapeutics
$8.92 /

+0.79 (+9.72%)

03/30/20 Nomura Instinet
Voyager Therapeutics price target lowered to $16 from $37 at Nomura Instinet
03/19/20
Fly Intel: Top five analyst initiations
03/19/20 Benchmark
Benchmark starts Voyager Therapeutics at Buy with $18 price target
03/19/20 Benchmark
Voyager Therapeutics initiated with a Buy at Benchmark
Recommendations
Crispr Therapeutics study halts not unexpected, says Piper Sandler » 06:17
04/01/20
04/01
06:17
04/01/20
06:17
CRSP

Crispr Therapeutics

$42.26 /

-2.08 (-4.69%)

Crispr Therapeutics…

Crispr Therapeutics disclosed last night that the Phase I/II CLIMB-Thal-111 and CLIMB-SCD-121 studies of CTX001 halted enrollment of beta thalassemia and sickle cell disease patients, Piper Sandler analyst Edward Tenthoff tells investors in a research note. This is not unexpected given these patients require lymphodepletion and may avoid immunosuppressive procedures, says Tenthoff. Further, the analyst belies that while enrollment continues for wholly-owned CD19 CAR-T CTX110 in B-cell malignancies and second CAR-T, CTX120 in relapsed/refractory multiple myeloma, the in-patient administration of CAR-T could slow enrollment. Nonetheless, Tenthoff reiterates an Overweight rating on Crispr shares with a $104 price target.

ShowHide Related Items >><<
CRSP Crispr Therapeutics
$42.26 /

-2.08 (-4.69%)

03/04/20 Stifel
Crispr Therapeutics initiated with a Hold at Stifel
02/13/20 Piper Sandler
Crispr Therapeutics ended year with $943M in cash, says Piper Sandler
02/03/20 Evercore ISI
Evercore ISI downgrades Crispr Therapeutics, questions relative valuation
02/03/20 Evercore ISI
Crispr Therapeutics downgraded to In Line from Outperform at Evercore ISI

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.